Long XMM observation of the Narrow-Line Seyfert 1 galaxy IRAS13224-3809: rapid variability, high spin and a soft lag

Results are presented from a 500ks long XMM-Newton observation of the Narrow-Line Seyfert 1 galaxy IRAS13224-3809. The source is rapidly variable on timescales down to a few 100s. The spectrum shows strong broad Fe-K and L emission features which are interpreted as arising from reflection from the inner parts of an accretion disc around a rapidly spinning black hole. Assuming a power-law emissivity for the reflected flux and that the innermost radius corresponds to the innermost stable circular orbit, the black hole spin is measured to be 0.988 with a statistical precision better than one per cent. Systematic uncertainties are discussed. A soft X-ray lag of 100s confirms this scenario. The bulk of the power-law continuum source is located at a radius of 2-3 gravitational radii.Comment: 7 pages, 14 figures, submitted to MNRA

The first three seconds: a review of possible expansion histories of the early universe

It is commonly assumed that the energy density of the Universe was dominated by radiation between reheating after inflation and the onset of matter domination 54,000 years later. While the abundance of light elements indicates that the Universe was radiation dominated during Big Bang Nucleosynthesis (BBN), there is scant evidence that the Universe was radiation dominated prior to BBN. It is therefore possible that the cosmological history was more complicated, with deviations from the standard radiation domination during the earliest epochs. Indeed, several interesting proposals regarding various topics such as the generation of dark matter, matter-antimatter asymmetry, gravitational waves, primordial black holes, or microhalos during a nonstandard expansion phase have been recently made. In this paper, we review various possible causes and consequences of deviations from radiation domination in the early Universe - taking place either before or after BBN - and the constraints on them, as they have been discussed in the literature during the recent years

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Probing the inflationary particle content: extra spin-2 field

We study how inflationary observables associated with primordial tensor modes are affected by coupling the minimal field content with an extra spin-2 particle during inflation. We work with a model that is ghost-free at the fully non-linear level and show how the new degrees of freedom modify standard consistency relations for the tensor bispectrum. The extra interacting spin-2 field is necessarily massive and unitarity dictates its mass be in the $m \gtrsim H$ range. Despite the fact that this bound selects a decaying solution for the corresponding tensor mode, cosmological correlators still carry the imprints of such "fossil" fields. Remarkably, fossil(s) of spin $\geq 1$ generate distinctive anisotropies in observables such as the tensor power spectrum. We show how this plays out in our set-up.Comment: 25 pages, 3 figure

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction &gt;0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease